Last Posted: Aug 10, 2019
- The role of ABO blood groups in glial neoplasms.
Alkan Ali, et al. British journal of neurosurgery 2019 2 (1) 43-46
- Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
Kuwahara Kiyonori, et al. Brain tumor pathology 2019 7
, ATRX , and BRAF V600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population.
Chatterjee Debajyoti, et al. Surgical neurology international 2018 0 29
- The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Yujin, et al. Acta neuropathologica communications 2017 8 (1) 62
- Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan K S, et al. Journal of clinical pathology 2016 1
- The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Kizilbash Sani H, et al. Journal of neuro-oncology 2014 10 (1) 85-93
- Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura Ryosuke, et al. Neuropathology : official journal of the Japanese Society of Neuropathology 2015 8 (4) 324-35
- Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
Chen J-R, et al. Acta neurologica Scandinavica 2015 4
- IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti Giuseppe, et al. Journal of neuro-oncology 2014 6 (2) 377-83
- Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
Zhang Chuan-Bao, et al. Journal of cancer research and clinical oncology 2014 1 (1) 45-51
- IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota Balaram, et al. American journal of clinical pathology 2012 8 (2) 177-84
- DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura Kazuya, et al. Journal of neuropathology and experimental neurology 2012 8 (8) 702-7
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann Christian, et al. Acta neuropathologica 2010 12 (6) 707-18
- MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
Groenendijk Floris H, et al. Journal of neuro-oncology 2011 2 (3) 405-17
- Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.
Kilburn Lindsay, et al. Cancer 2010 5 (9) 2242-9
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Quick Links to Other Resources
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.